About GAP
The data is clear: The Global Alzheimer’s PlatformFoundation (GAP) is the recognized leader in accelerating Alzheimer’s disease clinical trial timelines, recruiting diverse trial participants, and deploying innovative solutions. GAP is shortening the duration, reducing the cost, and improving the efficiency ofAlzheimer’s and Parkinson’s disease clinical trials.
Our Success
>90 sites have joined GAP-Net, our invitation onlynetwork of both private and institutional-based research centers
82% of GAP-Net sites leverage Central IRB servicesto speed study start-up
>4,500 rides provided for study participantsthrough our GAP | Lyft National Clinical TrialTransportation Service
Average randomization rates in GAP-enabled trials as high as .62 p/s/m across GAP-Net sites compared to sites not in GAP-Net
>30% faster in Study Start Up to FirstParticipant Screened
Up to 45% improvement in screening rates
Up to 19% improvement in randomization rates
Key Factors
- Keeping GAP-enabled trials at the forefront in crowded CNS clinical trial portfolios
- ~2,500 personalized visits with GAP-Net site staff enabling enhanced relationships and customized site solutions
- <5% turnover among our GPSLiaisons – all with extensive clinical trial experience and many from nationally recognized research institutions
2. Valued partner for sponsors, CROs and GAP-Net site staff: Due to on-demand and annual GAP-Net site collaboration activities to share expertise and overcome common barriers to clinical trial success
3. Forward thinking: GAP launched Bio-Hermes, a blood and digital biomarker study, to provide data to optimize screening.Study has an aggressive 20% minimum endpoint for enrollment of Black/AfricanAmericans and Hispanic/Latinos
4. Prioritizes intentional inclusion of traditionally underrepresented populations as trial participants, with a multi-faceted approach focused on awareness, knowledge and access and built on collaborative relationships with trusted local organizations